Stock of the Day

April 13, 2021

Seagen (SGEN)

$228.74
$0.00 (0.0%)
Market Cap: $42.93B

About Seagen

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Seagen Bull Case

Here are some ways that investors could benefit from investing in Seagen Inc.:

  • Seagen Inc. has a strong portfolio of innovative cancer therapies, including ADCETRIS and PADCEV, which are well-established in the market and have shown significant efficacy in treating various cancers.
  • The company is actively developing new treatments, such as TIVDAK for metastatic cervical cancer, which could expand its market reach and revenue potential.
  • As of February 19, 2025, the stock price of Seagen Inc. is competitive, reflecting investor confidence in its growth prospects and the ongoing demand for cancer therapies.
  • Seagen Inc. has established collaboration agreements with major pharmaceutical companies, enhancing its research capabilities and market access, which can lead to increased revenue streams.
  • The recent acquisition by Pfizer Inc. positions Seagen Inc. for greater resources and support, potentially accelerating its development pipeline and market presence.

Seagen Bear Case

Investors should be bearish about investing in Seagen Inc. for these reasons:

  • Despite its strong product lineup, Seagen Inc. faces intense competition in the biotechnology sector, which could impact its market share and pricing power.
  • The biotechnology industry is subject to regulatory scrutiny, and any delays or issues in obtaining approvals for new therapies could adversely affect the company's growth trajectory.
  • Seagen Inc. relies heavily on a few key products for revenue, making it vulnerable to market fluctuations or changes in treatment guidelines that could affect sales.
  • Investors may be concerned about the high costs associated with research and development in biotechnology, which can lead to significant financial losses if new products do not succeed.
  • The recent acquisition by Pfizer Inc. may lead to uncertainties regarding Seagen Inc.'s strategic direction and operational independence, which could affect investor confidence.